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Palliative care for people with advanced 
liver disease: A feasibility trial of a 
supportive care liver nurse specialist
Barbara Kimbell1, Scott A Murray1 , Heidi Byrne2, Andrea 
Baird2, Peter C Hayes2, Alastair MacGilchrist2, Anne Finucane3, 
Patricia Brookes Young4, Ronan E O’Carroll5, Christopher J 
Weir6, Marilyn Kendall1 and Kirsty Boyd1
Abstract
Background: Liver disease is an increasing cause of death worldwide but palliative care is largely absent for these patients.
Aim: We conducted a feasibility trial of a complex intervention delivered by a supportive care liver nurse specialist to improve care 
coordination, anticipatory care planning and quality of life for people with advanced liver disease and their carers.
Design: Patients received a 6-month intervention (alongside usual care) from a specially trained liver nurse specialist. The nurse 
supported patients/carers to live as well as possible with the condition and acted as a resource to facilitate care by community 
professionals. A mixed-method evaluation was conducted. Case note analysis and questionnaires examined resource use, care 
planning processes and quality-of-life outcomes over time. Interviews with patients, carers and professionals explored acceptability, 
effectiveness, feasibility and the intervention.
Setting/participants: Patients with advanced liver disease who had an unplanned hospital admission with decompensated cirrhosis 
were recruited from an inpatient liver unit. The intervention was delivered to patients once they had returned home.
Results: We recruited 47 patients, 27 family carers and 13 case-linked professionals. The intervention was acceptable to all 
participants. They welcomed access to additional expert advice, support and continuity of care. The intervention greatly increased the 
number of electronic summary care plans shared by primary care and hospitals. The Palliative care Outcome Scale and EuroQol-5D-
5L questionnaire were suitable outcome measurement tools.
Conclusion: This nurse-led intervention proved acceptable and feasible. We have refined the recruitment processes and outcome 
measures for a future randomised controlled trial.
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What is already known about the topic?
•• Palliative care is available increasingly for people with advanced heart, lung and kidney disease but tends to be absent or 
very late for people with liver disease.
•• Liver disease is a rising cause of death worldwide, affecting younger people and often ending with a hospital death.
•• Effective identification, ongoing support and care planning can improve quality of life for people with advanced liver 
disease.
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What this paper adds?
•• A liver nurse specialist intervention proved acceptable and feasible.
•• Patients, families and professionals valued and benefitted from support and case management from a liver nurse specialist 
with some generic palliative care training.
•• The trial successfully identified recruitment processes, refined an acceptable intervention and tested the feasibility of 
collecting candidate outcome measures.
Implications for practice, theory or policy
•• This feasibility trial provided valuable information to inform the design of a future randomised controlled trial of a nurse-
led intervention to improve the care of people with advanced liver disease.
Introduction
Liver disease is an increasing cause of death worldwide, 
with 90% of deaths under 70 years.1,2 Its trajectory is 
erratic and unpredictable, with increasingly frequent, 
unplanned hospital admissions.3 Patients experience many 
physical and psychosocial challenges including fatigue, 
anxiety and depression.4 Their everyday life is disrupted 
and uncertainty prevails.5 Comorbidities are common and 
70% of deaths occur in hospital.2
Palliative care is available increasingly for people 
with heart, lung and kidney failure.6 However, support-
ive and palliative care needs in people with liver failure 
often go unrecognised and unaddressed.7,8 This is 
despite many national policies and the World Health 
Organization (WHO) calling for palliative care to be 
delivered according to need.9–11 Compared with other 
advanced progressive illnesses such as cancer, heart 
failure, respiratory disease or neurological conditions, 
involvement of nurse specialists is rare. In liver units, 
they usually support people being assessed for liver 
transplantation or work in hepatitis C services.12 
Supportive care in the community, integrated with hos-
pital hepatology/gastroenterology services, is increas-
ingly seen as important.13 Effective identification, 
ongoing support and anticipatory care planning should 
enable people with advanced liver disease to maximise 
their quality of life and reduce the burden of unplanned 
hospital admissions that are so common in their final 
year of life.
Randomised controlled trials (RCTs) in liver failure 
focus predominantly on managing physical complica-
tions.14 We found no trials of palliative care for people 
with advanced liver disease; however, a quality improve-
ment project of early palliative care for patients await-
ing liver transplantation suggested that it could deliver 
potential improvements in symptom burden and mood.15 
Evidence-based models in cancer have successfully 
introduced palliative care earlier and integrated with 
care by other specialists.16,17 Management of advanced 
liver disease can be complex and requires specific 
expertise that may not be available from palliative 
care clinicians or primary care teams.18 Integration of 
palliative care principles into the existing role of hepa-
tology teams is potentially more acceptable, deliverable 
and accessible. We developed an intervention to deliver 
this model of care and assessed it within a feasibility 
trial.
We evaluated the feasibility of a nurse-led, supportive 
care intervention for patients with advanced liver disease 
for whom liver transplantation was contraindicated. We 
aimed to answer three questions:
1. Was the supportive care service acceptable to 
patients, their informal carers and health 
professionals?
2. How could this intervention be improved to ensure 
that it is robust, feasible, deliverable and poten-
tially cost effective as part of routine health and 
social care services?
3. Is a randomised trial feasible in terms of recruit-
ment, retention and qualitative and quantitative 
data collection to measure primary and secondary 
outcomes?
Method
We conducted a feasibility trial with a mixed-method eval-
uation.19,20 The study was designed, conducted and evalu-
ated in collaboration with a patient and public involvement 
(PPI) group with extensive experience of advising on 
research in end-of-life care.
Recruitment and sample characteristics
We recruited patients aged over 18 with decompensated 
cirrhosis and their families from a tertiary gastroenter-
ology/hepatology hospital ward in Scotland (April 
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2015–February 2016). Patients were eligible if they had 
two or more hospital admissions with advanced liver 
disease related to complications of ascites, gastrointes-
tinal haemorrhage, encephalopathy, hepatorenal failure, 
sepsis or progressive hepatocellular carcinoma. We 
excluded patients with an expected survival of under 
1 month, other conditions likely to cause death within 
12 months, persistent cognitive impairment (assessed 
with the 4AT screening tool21) or those who lived over 
50 miles from the recruitment site to make qualitative 
interviews at home feasible. We chose not to include 
patients on the transplant waiting list as they were 
already receiving care coordination from designated 
liver specialists. Patients nominated their main informal 
carer who was also invited to participate. Their general 
practitioner (GP) was recruited by letter.
The intervention
Two liver nurses with over 10 years of liver nursing 
experience shared the role and delivered the interven-
tion for 21 h per week. In addition to completing a Good 
Clinical Practice in research course, they received spe-
cific training in palliative care consisting of an advanced 
communication topic workshop on talking about dete-
riorating health and opportunities to shadow palliative 
care staff working in hospital, hospices and the com-
munity. They also accompanied a heart failure nurse 
specialist on home visits. After an initial face-to-face 
assessment and care coordination meeting with the 
patients and their informal carers, the liver nurses pro-
vided supportive care mainly by telephone for up to 
6 months (alongside the patients’ usual care). The sup-
portive care liver nurse specialist had three defined 
roles:
•• Act as a case manager and coordinator liaising 
between patients/carers, health and social care pro-
fessionals or services, and voluntary agencies;
•• Support patients and informal carers to live as well 
as possible by offering information about the illness 
and its management including financial and social 
support, providing psychological support and 
empowering patients/carers to seek help;
•• Support care delivered by professionals in the 
community through providing information and 
advice on the best practice (including integration 
of disease-focused treatments with supportive and 
palliative care) and facilitating anticipatory care 
planning through the use of the Scottish electronic 
summary care plan (Box 1). This is completed in 
primary care and accessed by emergency services 
and hospital staff. Details of the components and 
the delivery process of the intervention are shown 
in Figure 1.
Box 1. The Scottish Key Information Summary.
Introduced in 2013, the Key Information Summary (KIS) 
is a shared electronic medical record between healthcare 
professionals in Scotland. Using a template within the 
GP clinical system, a KIS is written for patients with the 
most complex care needs and notes key points of their 
anticipatory care plan, for example, medications, carer and 
next of kin details, the person’s wishes regarding place 
of death and resuscitation. The form may be updated as 
the patient’s condition progresses. It can be accessed by 
Out of Hours and some other services, for example, Acci-
dent & Emergency, Acute Receiving Unit and the Scottish 
Ambulance Service. Although other services can read a 
KIS, presently only General Practices can add informa-
tion to the document. For further details, see http://www.
scimp.scot.nhs.uk/key-information-summary/
Evaluation of the intervention
Five datasets were integrated to provide a comprehensive, 
mixed-method evaluation. Anonymity of patient/carer/pro-
fessional data was assured by assigning each patient a num-
ber at recruitment, which was used on all documentation and 
retained securely. Health and care resource use was moni-
tored for the duration of the intervention period; number of 
planned and patient/carer-initiated contacts with the nurse, 
number and duration of unplanned and elective hospital 
admissions, reason(s) for admission, hepatology outpatient 
visits, primary care team contacts, use of informal and for-
mal support agencies, place and cause of death; time from 
Figure 1. Components and delivery process of the 
intervention.
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recruitment to death. All correspondence and the clinical 
records of interactions with the nurses were documented, 
anonymised and analysed. Questionnaires for patients and 
family carers were presented in attractive, readable booklets 
and approved by our PPI group. The questionnaires were 
chosen on the basis of extensive use for previous research in 
palliative care populations, ease of completion to reduce par-
ticipant burden, and to provide a spectrum of complementary 
measures that could be considered for suitability in a large 
trial. They were administered by the nurse at baseline after 
recruitment to the study and sent by post at 3 and 6 months. 
Patients completed the Palliative care Outcome Scale (POS), 
which is a brief measure of palliative care service out-
comes;22 the EuroQol-5D-5L, which assesses quality of life 
and can inform economic evaluations;23 the Hospital Anxiety 
and Depression Score (HADS), to screen for anxiety and 
depression which are common psychological symptoms in 
people with advanced illness;24 and the McGill Quality of 
Life questionnaire Part B, which invites participants to iden-
tify up to three troublesome physical symptoms or problems 
and rate their severity.25 Family carers completed the POS 
Carer Score and the Caregiver Quality of Life questionnaire 
to assess the impact of the intervention on the carer experi-
ences.26 Qualitative interviews with a purposive sample of 
patients representing a range of aetiologies, demographics 
and care arrangements, their family carers and case-linked 
health and care professionals were conducted, using topic 
guides, by a female non-clinical researcher (B.K.). Her pre-
vious PhD had involved conducting in-depth, serial inter-
views with people with advanced liver disease.27 The 
interviews explored the acceptability, feasibility and per-
ceived impact of the intervention. Patients and carers were 
interviewed (either alone or together if they preferred) for 
20–60 minutes in the person’s home shortly after their initial 
face-to-face meeting with the nurse, 3 and 6 months later. 
Professionals were interviewed once, face-to-face or by tel-
ephone, at the end of the intervention.
Data analysis
The audio-recorded qualitative data and field notes were 
coded and analysed thematically according to the research 
questions and any emerging themes using NVivo qualitative 
data management software version 10 (QSR International 
(UK) Limited, London, UK). Questionnaire data were ana-
lysed using SPSS for Windows version 19 (IBM Corp., 
Armonk, NY). Descriptive statistics were used for the sample 
characteristics and quality-of-life outcomes. Continuous 
measures were summarised using the mean and standard 
deviation where these were normally distributed data and, if 
not, using the median and the interquartile range. Categorical 
variables were summarised by the frequency in each category. 
Outcomes were compared between time points using 
repeated-measures one-way analysis of variance (ANOVA) 
for normally distributed data and the Friedman test otherwise. 
Documentation generated by the nurses for each participant 
was reviewed systematically for type and content of interac-
tion and resultant actions. Emerging findings were regularly 
discussed with the wider research team and the PPI group.
Results
Feasibility of the intervention and evaluation
We recruited 47 patients over 46 weeks from gastroenterol-
ogy/hepatology inpatient wards and outpatient clinics, of 
whom 13 died or were lost to follow-up before starting the 
intervention; hence, 34 (72%) went on to receive the inter-
vention (Figure 2). Patient characteristics are shown in 
Table 1. During the initial 12 weeks, 82 of the 108 inpatients 
screened did not have multiple admissions as per the origi-
nal inclusion criterion, so we revised this to ‘one or more’ 
unplanned hospital admissions to facilitate subsequent 
recruitment. The clinicians decided that this intervention 
could improve care for patients following any hospital 
admission with decompensated, advanced liver disease and 
so recommended this change. A family carer was nominated 
by 27 patients and all agreed to participate.
Of the 34 intervention patients, 27 (79%) were alive at 
study completion. The seven patients who died during the 
intervention were in the study for a median of 124.5 days. 
Six patients died in hospital from acute complications of 
advanced cirrhosis. None were admitted for terminal care 
and all admissions were considered clinically appropriate by 
the ward team. In total, 14 (52%) carers left the study due to 
patient death (n = 10), patient withdrawal (n = 1), relation-
ship breakup (n = 1) and loss of interest (n = 2). We success-
fully recruited our target population of people with advanced 
liver disease at high risk of death but not imminently dying 
and their family carers. Resource use data including planned 
and unplanned hospital admission days and outpatient visits 
proved feasible to collect from hospital records. Of the 34 
case-linked GPs, 18 provided patient contact data.
Questionnaire pack return rates were high at the initial 
time point, indicating that the instruments and delivery 
methods used were acceptable. Due to death, attrition and 
non-returns, only 14 patients returned their questionnaire 
packs at all three time points (30% of those recruited), with 
lower completion rates for some questionnaires. The rate 
of return for carer questionnaires was also high initially, 
but fell over time (Table 2).
This feasibility study was not designed or powered to 
detect changes. However, exploratory data analysis revealed 
statistically significant improvements in key palliative care 
outcomes (POS) and quality of life (EQ-5D) over time (Table 
3). The HADS showed little change in patient depression and 
anxiety, but its value may have been limited because fatigue 
and poor sleep are increasingly frequent symptoms as the 
liver function worsens. Likewise, the rating scales of the 
McGill tool seemed to be difficult for some participants to 
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complete adequately. Six carers completed both the Carer 
POS and the Carer Quality of Life Index Scale at all three 
time points, but it was difficult to evaluate these data further 
due to our small sample size and participant attrition. The 
service use data did not show any reduction in hospital bed-
nights and outpatient attendances after the intervention 
started, although some patients did give accounts of instances 
where this had happened in their interviews.
For the qualitative interviews, all those we sampled 
agreed to an initial interview (13 patients, 10 family carers 
and 13 professionals), yielding 42 interviews (20 of these 
jointly with patient and carer). Only two patient–carer 
pairs opted out of follow-up interviews, confirming the 
acceptability and feasibility of multi-perspective, longitu-
dinal, qualitative interviewing in this patient group.
Acceptability of the individual components 
of the intervention to patients, families and 
professionals
The initial face-to-face meeting was widely considered 
helpful due to the time pressures typical of medical 
appointments and the nurses’ informal approach. Visiting 
the patient’s home for this meeting was valued as it allowed 
the nurses to see people’s living arrangements and gauge 
the person’s support needs at home:
We felt we were getting more answers, whereas in the hospital 
you feel as if it is, ‘We’re too busy, we’ve got other patients, 
you’re not the only patient, we’ve got this patient to see’. […] 
When [study nurse] was here we got a chance to speak. It was 
good, we did get a lot of feedback; it was really helpful. 
(Patient and carer 30)
I think it was nice they came to the house after [patient] came 
home because then they know how you’re living, you know? 
If you were sitting in rented accommodation that was terrible 
they know the home life is sad or poor or whatever and they 
can support you. It’s good that they know your home 
surroundings as well and who you have at home, if you have 
nobody, you know. (Patient and carer 34)
The dedicated telephone line received a high number 
of calls (70 calls by patients, 44 calls by family carers and 
28 by professionals). Participants considered the fre-
quency of the planned monthly calls by the nurse to be 
Figure 2. Flowchart of patient recruitment.
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adequate. Some felt that they could manage with fewer or 
no calls as long as they had access to a designated tele-
phone number to contact the nurses if needed. The 
monthly calls were considered particularly valuable to 
socially isolated patients:
I think psychologically knowing that [the study nurses] 
were there if I needed them and the fact they were going to 
call me in a month anyway, that’s probably helpful in itself. 
(Patient 07)
Professionals particularly valued the quick resolution 
of clinical questions and problems, help with complex 
symptom management, support in decision-making about 
whether admission was required and the nurse’s ability to 
fast-track admission when needed:
To me she was like the missing link that could explain 
everything to everybody and certainly was a great support to 
[patient] and his family. (Social Worker 41)
[Study nurse]’s name appears in the notes on six different 
dates, referring to discussions had with her to do with 
symptom management or arranging admission. (GP 23)
Modifications to the intervention suggested by 
participants
The qualitative interviews generated several suggestions 
for improving the intervention in a future trial. Many 
patients and family carers would have appreciated the 
nurse support earlier in their illness journey and more fre-
quent face-to-face meetings:
Table 2. Questionnaire returns over time.
Patient questionnaires Baseline (n = 42; %) 3 months (n = 31; %) 6 months (n = 27; %)
POS 100 77 48
HADS 98 81 52
EQ-5D 100 81 52
EQ-VAS 90 81 48
McGill 95 81 48
Continuity of care 88 81 52
Carer questionnaires Baseline (n = 27; %) 3 months (n = 17; %) 6 months (n = 13; %)
Carer POS 89 71 46
Carer QOL 85 71 38
POS: Palliative care Outcome Scale; HADS: Hospital Anxiety and Depression Score; EQ-5D: EruQol-5D; EQ-VAS: EuroQol-Visual Analogue Scale; 
QOL: quality of life.
n = number of questionnaires distributed; a returned questionnaire is a questionnaire returned with at least one item completed.
Table 1. Patient characteristics at time of recruitment.
No. of patients recruited 47
Male/female 31/16
Age Mean 60.5 years (range 31–87 years)
Liver disease aetiology 31 alcohol-related liver disease (ALD)
5 non-alcoholic fatty liver disease
10 combination of causes
1 unknown
Carstairs deprivation score28 Mean 3.5; median 4
(1 = most affluent, 7 = most deprived)
Time since diagnosis of cirrhosis Mean 2.7 years (range 0–12 years)
Hepatology clinical scoresa MELD: mean 16; median 16 (range 6–29)
Child–Pugh: mean 10; median 9 (range 6–12)





No. of ward admissions showing previous usage In previous 5 years: mean 3.8; median 3 (range 1–17)
In previous 12 months: mean 2.6; median 2 (range 0–9)
No. of inpatient days in the previous 12 months Mean 22.8 days; median 16 (range 0–78 days)
MELD: Model for End-Stage Liver Disease.
aDifferent scoring systems exist to predict the prognosis of patients with chronic liver disease and to determine the need for liver transplantation. 
MELD score is calculated from the patient’s serum bilirubin, serum creatinine and the international normalised ratio (INR) for prothrombin time. A 
score of 10–19 indicates a 6% 3-month mortality. Child–Pugh considers bilirubin, serum albumin, prothrombin time and prolongation, ascites and 
hepatic encephalopathy. A score of 10–15 indicates a 45% chance of 1-year survival.
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Interviewer: So would you have found having the sort of 
facility that the study nurses provided, having that earlier on, 
would that have been helpful or did it come at the right time?
Carer 46: No. I think even earlier on, because there was lots of 
questions, you don’t get told everything.
I think maybe in person would be a better option rather than a 
phone call, because […] if you were seeing that person face-
to-face on a regular basis and you get to know that person then 
you can sort of, you tend to open up a wee bit more. (Carer 30)
Professional suggestions related to alternative ways of 
engaging with the nurse and additional responsibilities for 
the role and explicitly suggesting a shared-care model with 
primary care:
If they maybe had some clinical responsibilities then knowing 
these patients, going and seeing them, they should be able to 
say, ‘Right, you need to go into hospital’, and sort all that out 
and in a sense bypass us. So that might be an area where it 
might be able to be developed. (GP 42)
We’ve got the renal advice service and we just ping off an 
email […] and usually that is replied to within 24 hours, so we 
can get an answer about what to do with complicated patients, 
without necessarily being on hold to a registrar who doesn’t 
know them so well […]You don’t want delays to happen if 
patients really need to be in hospital, but email would be one 
option, some kind of direct advice line would be great. (GP 
23)
Something summarising the anticipated prognosis […] that’s 
very helpful to allow us to have an initial pegging process to 
know where to pitch them in our order of priority. So people 
who are expected to do very well we would be less concerned 
about, but people who are going to have very frequent regular 
reviews, they will be brought to our attention much more 
readily if that is set out in a succinct summary from the liver 
clinic. That would be very helpful to know, how worried to be 
about them. (GP 36)
Impact of the intervention
The advice, support and continuity of care provided by the 
supportive care liver nurse intervention improved partici-
pants’ ability to cope:
[Study nurse] was very helpful, she put my mind at rest, she 
answered questions that I hadn’t thought about, and she gave 
me more confidence to be able to deal with what I’m doing. 
(Carer 31)
Some patients and family carers reduced their contacts 
with their GP, instead using the study nurse as first point of 
call for queries and concerns, with welcome consequences 
for busy community professionals:
It’s taking some workload off us, because [patient]’s not been 
in contact nearly as frequently as previously. (GP 26)
The study nurses successfully case-managed several 
patients who had otherwise disengaged from routine ser-
vices. Their involvement also resulted in more timely, 
planned and person-centred hospital admissions:
[Study nurse] made [consultant] aware, the GI team aware, 
so we didn’t have to hang about A&E for a long time. They 
knew and came down almost immediately. Which is fine 
Table 3. Outcomes’ scores over time.
Outcomeb Baseline 3 months 6 months Change
POS (n = 11)
Mean 19.45 14.18 14.73 p = 0.001*
SD 6.80 9.11 9.41  
EQ-5D index (n = 13)a
Median 0.50 0.69 0.67 p = 0.037*
IQR 0.33 0.22 0.32  
EQ-VAS (n = 11)
Mean 41.82 51.36 62.27 p = 0.004*
SD 16.47 18.97 13.67  
HADS–Anxiety (n = 14)
Mean 10.07 8.79 9.14 p = 0.43
SD 5.20 5.96 4.27  
HADS–Depression (n = 14)
Mean 9.57 8.86 8.93 p = 0.74
SD 2.95 4.31 4.07  
POS: Palliative care Outcome Scale; SD: standard deviation; IQR: interquartile range; HADS: Hospital Anxiety and Depression Score.
aAnalysed using the Friedman test; repeated-measures one-way ANOVA was used for all other outcomes.
bBased on those who completed a questionnaire at all three time points only.
*Highlights statistically significant improvements.
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now, that’s kind of what happens, he’s normally seen pretty 
quickly. (Carer 08)
The nurses’ initial review meetings with patients and 
carers showed that patients generally had a poor under-
standing of their illness and its likely course and this ham-
pered anticipatory care planning. However, the nurses’ 
correspondence prompted 21 GPs to create a new anticipa-
tory care plan, while 8 updated a patient’s existing plan. 
The intervention thus increased the proportion of updated 
electronic summary care plans created in primary care and 
accessible to other staff in the community and hospitals 
from 29% before the intervention to 85% after it.
Discussion
Summary
The nurse-led intervention proved acceptable and feasible. 
Patients, families and professionals valued and benefitted 
from the support of a skilled nurse specialist and case man-
ager. The nurse’s ability to help patients, carers and profes-
sionals to cope with the uncertainties inherent in managing 
advanced liver disease was appreciated.27 Improvements to 
people’s quality of life and care were demonstrated through 
the interviews and improvements in the quality-of-life ques-
tionnaire scores. Improvements in care coordination were 
evident from the study nurses’ engagement with profession-
als across a range of settings, their key role in facilitating 
more efficient hospital admissions and the informational and 
relational continuity of care the role afforded to patients, car-
ers and professionals. Care planning became proactive and 
routine instead of opportunistic, with a marked improvement 
in the number and timely completion and updating of elec-
tronic summary care plans. These are of proven value for 
facilitating anticipatory care planning across settings in 
Scotland.28 Evidence from several participants indicated that 
the specialist nurse intervention has the potential to reduce 
unplanned hospital admissions. Other possible service use 
and economic benefits of the intervention are its potential to 
reduce outpatient clinic non-attendance, decrease primary 
care appointments and visits, and facilitate earlier discharge.
Comparison with the current literature
Most recent trials to integrate palliative care earlier in the 
illness trajectory of people with advanced diseases in gen-
eral have involved the addition of specialist palliative care 
in parallel with continuing disease management.29–31 
However, the WHO recommends a ‘palliative care 
approach’ that is delivered by the clinician or team already 
involved in the patient’s ongoing care.11 A recent system-
atic review has reported how this can be conducted by 
clinical nurse specialists, but found no such studies in liver 
disease.32 Baumann et al.15 have demonstrated that 
integrating early palliative care into the pre-transplant 
assessment process can be beneficial. This feasibility trial 
successfully developed and evaluated an innovative inter-
vention that can be embedded in an existing gastroenterol-
ogy/hepatology hospital service and then extended into the 
community through education and support. It is widely 
replicable and has the potential to improve quality of life 
for patients and families alongside optimising resource 
use. We have also tested this approach to integrated sup-
portive and palliative care for people with heart disease.33
The liver nurses considered the palliative care training 
they received at the start of the study to be crucial in building 
their confidence in conducting sensitive conversations about 
deteriorating health and anticipatory care planning, and 
increasing their understanding of community care. However, 
our findings indicated that expertise in identifying and man-
aging the complexities of caring for people with liver disease 
was more critical to this role than specialist palliative care 
experience. Following a period of targeted education, and 
with access to specialist palliative care advice where needed, 
the study nurses were able to tailor and apply palliative care 
principles in a complex patient group not routinely referred 
to palliative care services except close to death. The contri-
bution of specialist nursing roles to the experience and out-
comes of care has been recognised in relation to other 
non-malignant illnesses, cancer and palliative care.34,35 This 
study highlights the positive potential of the specialist nurs-
ing role in the care of people with advanced liver disease.
Limitations and strengths
The study was limited to a small number of white patients, 
largely with alcohol-related liver disease, attending one 
specialist centre in Scotland. The intervention lasted only 
6 months and this limited our ability to fully test the 
validity of some of the questionnaires. Collection of 
community health and care service use data was more 
challenging than measuring hospital resource use, but 
new national datasets are likely to increase access to 
these outcome measures in future.
This is the first feasibility trial of integrating a palliative 
care approach within the role of a liver nurse specialist. We 
were able to identify and recruit patients who benefitted 
from early integrated supportive care, without them or the 
professionals involved being deterred using the term ‘pal-
liative care’, which for many people is still associated with 
imminent death. A frequently cited trial providing early 
palliative care in oncology judged that a full RCT is feasi-
ble if at least 50% of recruited patients participated in an 
initial care review meeting and completed the study ques-
tionnaires.36 Using this criterion, our feasibility trial was 
successful; we achieved 64% participation, with no subse-
quent attrition except through death.
Evaluation of palliative care in an unpredictable and 
complex illness trajectory like liver disease is particularly 
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challenging. Single index measures are unlikely to capture 
the breadth of important outcomes for patients, family car-
ers, professionals and healthcare organisations.37,38 
Palliative care interventions typically support multiple 
dimensions of need, and thus measures to assess these are 
indicated. It is also known in palliative care that access to 
a service may be appreciated, even if the service is not 
utilised. A wider range of measures used longitudinally 
over the course of the illness trajectory should be consid-
ered. We used a mixed-method evaluation which provided 
valuable, multi-faceted outcome data over time. In liver 
disease, the rapid onset of potentially life-threatening com-
plications means that it is important not to focus too nar-
rowly on place of death as a primary outcome.
Recommendations for a future RCT
We have presented a set of outcome measures and comple-
tion rates that can inform sample size calculations for a 
controlled trial. Future inclusion criteria should be broad-
ened to include a first admission with complications of cir-
rhosis. Multiple sites should be considered to optimise 
recruitment and generalisability. The next trial should seek 
randomisation to the intervention against continuation of 
current best practice.
Late recruitment to the study and challenges with secur-
ing follow-up interviews due to patients’ fluctuating health 
indicate that a future trial operating a 6-month intervention 
could consider reducing interviews to two time points – 
baseline and 6 months.
The POS and the EuroQol-5D-5L are recommended as 
outcome measures. Supporting patients to complete these 
by phone, app, video call or in person should be consid-
ered to improve return rates. If carer questionnaires are to 
be used, such individual support may also be required. 
Alternatively, qualitative methods might be more appro-
priate to gather information on carer perspectives. 
Resource utilisation and health economic data and process 
measures such as the number of advance/anticipatory care 
plans or electronic summary care plans generated should 
also be collected. The choice of analytical strategy to com-
pare functional outcomes in RCTs with high mortality 
where outcomes are ‘truncated due to death’ deserves spe-
cial considerations.39 Each statistical approach relies on 
certain assumptions, and analysis must be mindful of the 
possible effects of the treatment on mortality.
The trial intervention might include a greater emphasis 
on educating and supporting primary care professionals to 
provide holistic care for people with advanced liver disease 
as they reported a lack of knowledge and confidence.
Conclusion
Further studies assessing palliative care interventions for 
people with end-stage liver disease are needed.41 This 
study provided valuable information to inform the design 
of a future RCT of a specialist supportive care nurse inter-
vention to improve the care of people with advanced liver 
disease. It successfully identified recruitment processes, 
refined an acceptable intervention and tested the feasibility 
of collecting candidate outcome measures.
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